Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.
While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM ESTWells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.
"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.
Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.
... More